Drug Trial Radar · NCT06667141
Study of ACR-2316 in Specific Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
Aug 12, 2027
Study completion Dec 12, 2027
Sponsor
- Lead sponsor
- Acrivon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in-human, Open-label Phase 1/2 study to assess the safety and activity of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Conditions
- Specific Advanced Solid Tumors
Interventions
ACR-2316Drug
ACR-2316 is an experimental drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose EscalationTime frame: Number of DLT events during the DLT observation period (up to 28 days)
- Dose ExpansionTime frame: RP2D supported by safety, PK and PD data through study completion
- Dose ExpansionTime frame: Incidence and grades of TEAEs and TRAEs per NCI CTCAE v.5.0 and number of dose decreases, number of dose delays, and SAEs through study completion, an average of 1 year.
- Dose ExpansionTime frame: Confirmed ORR per Recist v1.1 and DOR, CBR, assessed every 6 weeks from baseline thorough study completion, an average 1 year or until death.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Phoenix, Arizona · Recruiting
Precision NextGen Oncology & Research Center
Beverly Hills, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
Denver Health One
Denver, Colorado · Recruiting
Florida Cancer Specialist
Sarasota, Florida · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Montefiore Medical Centre
The Bronx, New York · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
Tennessee Oncology
Franklin, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
Next Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.